emergencydrug
New member
Briganix (Brigatinib) 180 MG is classified as an anti-cancer (antineoplastic) medicine. It operates as a targeted therapy, distinct from traditional chemotherapy drugs.
Brigatinib, initially known as AP26113, serves as a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It demonstrates selectivity against mutant forms of EGFR and various Crizotinib-resistant mutants of the EML4-ALK fusion gene. This targeted inhibition curtails the growth of cancerous cells while sparing healthy ones.
Brigatinib, initially known as AP26113, serves as a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It demonstrates selectivity against mutant forms of EGFR and various Crizotinib-resistant mutants of the EML4-ALK fusion gene. This targeted inhibition curtails the growth of cancerous cells while sparing healthy ones.